Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea

Description

The purpose of this study is to learn more about how to improve treatment of patients with diarrhea predominant Irritable Bowel Syndrome (IBS-D) symptoms.Included patients will be requested to answer online surveys and will undergo treatment with rifaximin. Hydrogen breath testing and biologic samples collection will also be completed during the study.

Conditions

Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to learn more about how to improve treatment of patients with diarrhea predominant Irritable Bowel Syndrome (IBS-D) symptoms.Included patients will be requested to answer online surveys and will undergo treatment with rifaximin. Hydrogen breath testing and biologic samples collection will also be completed during the study.

The Role of Breath Testing in Enriching the Likelihood of Response to Rifaximin in Patients With Diarrhea IBS

Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea

Condition
Irritable Bowel Syndrome
Intervention / Treatment

-

Contacts and Locations

Ann Arbor

University of Michigan, Ann Arbor, Michigan, United States, 48109

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * IBS-D (Rome IV Diagnostic Criteria)
  • * Diary compliance for at least 5 days and no rescue medications during baseline
  • * Appropriate levels of abdominal pain and diarrhea
  • * Pregnant women or planning on becoming pregnant while in the study, or lactating women while in the study
  • * Inflammatory bowel disease, diabetes mellitus, systemic sclerosis, or celiac disease
  • * Active gastrointestinal or hematological malignancy which requires ongoing treatment
  • * Surgery to the GI tract in the past 3 months
  • * Gastrointestinal infection or diverticulitis in the past 3 months
  • * Severe hepatic impairment
  • * Any use of antibiotics in the past month
  • * Current use of probiotics
  • * Any history of allergies to rifaximin or its derivatives
  • * Any comitant use of P-glycoprotein inhibitors (for example. Cyclosporine)
  • * Known allergies to glucose or lactulose

Ages Eligible for Study

18 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Michigan,

William Chey, M.D., PRINCIPAL_INVESTIGATOR, University of Michigan

Study Record Dates

2025-01-01